Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2018 | Aug. 10, 2018 | |
Document Information [Line Items] | ||
Entity Registrant Name | SOPHIRIS BIO INC. | |
Entity Central Index Key | 1,563,855 | |
Trading Symbol | sphs | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 30,111,153 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 13,941 | $ 16,087 |
Securities available-for-sale | 4,587 | 9,757 |
Prepaid expenses and other current assets | 1,055 | 1,012 |
Total current assets | 19,583 | 26,856 |
Property and equipment, net | 3 | 2 |
Other long-term assets | 19 | |
Total assets | 19,586 | 26,877 |
Current liabilities: | ||
Accounts payable | 1,271 | 832 |
Accrued expenses | 2,662 | 1,499 |
Current portion of promissory note | 1,548 | 372 |
Total current liabilities | 5,481 | 2,703 |
Long-term promissory note | 5,362 | 6,435 |
Warrant liability | 10,099 | 10,089 |
Total liabilities | 20,942 | 19,227 |
Commitments and contingencies | ||
Shareholders’ (deficit) equity: | ||
Common shares, unlimited authorized shares, no par value; 30,111,153 shares issued and outstanding at June 30, 2018 and December 31, 2017 | 131,247 | 131,247 |
Contributed surplus | 26,274 | 25,854 |
Accumulated other comprehensive gain | 97 | 97 |
Accumulated deficit | (158,974) | (149,548) |
Total shareholders’ (deficit) equity | (1,356) | 7,650 |
Total liabilities and shareholders’ (deficit) equity | $ 19,586 | $ 26,877 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
Common shares, par value (in dollars per share) | $ 0 | $ 0 |
Common shares, shares issued (in shares) | 30,111,153 | 30,111,153 |
Common shares, shares outstanding (in shares) | 30,111,153 | 30,111,153 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Operating expenses: | ||||
Research and development | $ 3,591 | $ 1,387 | $ 6,920 | $ 2,595 |
General and administrative | 1,096 | 1,367 | 2,340 | 2,736 |
Total operating expenses | 4,687 | 2,754 | 9,260 | 5,331 |
Other income (expense): | ||||
Interest expense | (172) | (341) | ||
Interest income | 91 | 53 | 178 | 103 |
Gain (loss) on revaluation of warrant liability | (1,365) | 3,320 | (10) | 3,234 |
Other income (expense), net | 36 | (9) | 7 | (16) |
Total other income (expense) | (1,410) | 3,364 | (166) | 3,321 |
Net income (loss) | $ (6,097) | $ 610 | $ (9,426) | $ (2,010) |
Basic income (loss) per share (in dollars per share) | $ (0.20) | $ 0.02 | $ (0.31) | $ (0.07) |
Diluted income (loss) per share (in dollars per share) | $ (0.20) | $ 0.02 | $ (0.31) | $ (0.07) |
Weighted average number of outstanding shares – basic (in shares) | 30,111 | 30,111 | 30,111 | 30,111 |
Weighted average number of outstanding shares – diluted (in shares) | 30,111 | 30,515 | 30,111 | 30,111 |
Other comprehensive income (loss): | ||||
Unrealized income (loss) on securities available-for-sale | $ 2 | $ (1) | $ (14) | |
Total other comprehensive income (loss) | $ (6,095) | $ 609 | $ (9,426) | $ (2,024) |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Cash flows used in operating activities | ||
Net loss | $ (9,426) | $ (2,010) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation | 421 | 867 |
Accretion of debt discount | 75 | |
Amortization of promissory note issuance costs | 29 | |
Depreciation of property and equipment | 1 | 3 |
Amortization of premium/discount on securities available-for-sale | (35) | 92 |
Change in fair value warrant liability | 10 | (3,234) |
Foreign exchange transaction loss | 2 | 4 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other assets | (24) | (24) |
Accounts payable | 436 | 41 |
Accrued expenses | 1,162 | (608) |
Net cash used in operating activities | (7,349) | (4,869) |
Cash flows provided by (used in) investing activities | ||
Purchases of property and equipment | (3) | (1) |
Maturities of securities available-for-sale | 7,287 | 4,291 |
Purchases of securities available-for-sale | (2,081) | (5,400) |
Net cash provided by (used in) investing activities | 5,203 | (1,110) |
Cash flows provided by financing activities | ||
Proceeds from exercise of stock options | 2 | |
Net cash provided by financing activities | 2 | |
Effect of exchange rate changes on cash and cash equivalents | 1 | |
Net decrease in cash and cash equivalents | (2,146) | (5,976) |
Cash and cash equivalents at beginning of period | 16,087 | 12,800 |
Cash and cash equivalents at end of period | 13,941 | 6,824 |
Supplemental disclosures of non-cash investing and financing activities: | ||
Change in the fair value of stock-based compensation liability recorded to contributed surplus | $ (57) |
Note 1 - Nature of the Business
Note 1 - Nature of the Business | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Nature of the business Company Sophiris Bio Inc., or the Company, or Sophiris, is a clinical-stage biopharmaceutical company focused on innovative products for the treatment of urological diseases. The Company is governed by the British Columbia Business Corporations Act. The Company’s operations were initially located in Vancouver, British Columbia until April 2011, The condensed consolidated financial statements include the accounts of Sophiris Bio Inc. and its wholly-owned subsidiaries, Sophiris Bio Corp. and Sophiris Bio Holding Corp., both of which are incorporated in the State of Delaware. Liquidity The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. At June 30, 2018 $18.5 June 2019, one We are currently evaluating options to further advance the clinical development of topsalysin. We will require significant additional funding to advance topsalysin in clinical development. We could use dilutive funding options such as an equity financing and non-dilutive funding options such as a partnering arrangement or royalty agreement to fund future clinical development of topsalysin. At this point in time we do not 3 second 3 no If the Company is unable to raise additional capital to fund its development program efforts beyond its ongoing clinical trial in sufficient amounts or on terms acceptable to it, the Company may |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of significant accounting policies Basis of consolidation The condensed consolidated financial statements include the accounts of the Company, Sophiris Bio Corp. and Sophiris Bio Holding Corp. All intercompany balances and transactions have been eliminated for purposes of consolidation. Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, for the interim financial information and the rules and regulations of the Securities and Exchange Commission, or SEC, related to quarterly reports on Form 10 not 10 March 21, 2018. not not may During the six June 30, 2018, no 10 December 31, 2017, Revenue recognition Effective January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 606 The Company may may 606. The Company will then perform an analysis to determine the total transaction price that the Company expects to receive from satisfying the performance obligations in the agreement. To the extent that the agreement includes variable consideration, amounts which can vary depending on the occurrence or nonoccurrence of a future event, the amount included in the total transaction price may not not The calculated transaction price will then be allocated to the separate performance obligations based upon the relative standalone selling price of the performance obligations. If standalone selling price cannot be determined, a residual approach may For each performance obligation, the Company must determine the period over which the performance obligations will be satisfied, and revenue recognized. Revenue will be recognized over time if the Company satisfies the performance obligation over a period of time whereas revenue will be recognized at a point in time if the performance obligation is satisfied at a specific point in time. Revenue related to the transfer of an intellectual property license will be recognized either upon the transfer of the license or over a period of time depending upon whether or not not may Recent accounting pronouncements In February 2016, No. 2016 02, Leases (Topic 842 not December 15, 2018 In August 2016, 2016 15, "Statement of Cash Flows (Topic 230 eight first 2018, not In May 2017, No. 2017 09, "Compensation-Stock Compensation (Topic 718 2017 09. 718. first 2018, not |
Note 3 - Net Income (Loss) Per
Note 3 - Net Income (Loss) Per Common Share | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 3. Net income ( loss ) per common share Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to common shareholders by the weighted-average number of common shares outstanding during the period, without consideration for common shares equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common shareholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic net income (loss) per share Net income (loss) allocated to common stockholders $ (6,097 ) $ 610 $ (9,426 ) $ (2,010 ) Weighted average common shares outstanding-basic 30,111 30,111 30,111 30,111 Net income (loss) per share-basic $ (0.20 ) $ 0.02 $ (0.31 ) $ (0.07 ) Diluted net income (loss) per share Net income (loss) allocated to common stockholders-diluted $ (6,097 ) $ 603 $ (9,426 ) $ (2,010 ) Weighted average common shares outstanding-basic 30,111 30,111 30,111 30,111 Dilutive securities — 404 — — Weighted average common shares outstanding-dilutive 30,111 30,515 30,111 30,111 Net income (loss) per share-diluted $ (0.20 ) $ 0.02 $ (0.31 ) $ (0.07 ) The following diluted securities were excluded from the calculation of the denominator for diluted net income per common share for the three six June 30, 2018 2017 Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Options to purchase common shares 2,940 2,497 2,940 2,888 Common share purchase warrants 5,825 5,712 5,825 5,725 |
Note 4 - Securities Available-f
Note 4 - Securities Available-for-sale | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] | 4. Securities Available-for-Sale Securities available-for-sale consisted of the following as of June 30, 2018 ( June 3 0 , 2018 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 2,093 $ — $ — $ 2,093 U.S. government sponsored enterprise securities 2,496 — (2 ) 2,494 $ 4,589 $ — $ (2 ) $ 4,587 As of June 30, 2018, one Securities available-for-sale consisted of the following as of December 31, 2017 December 31, 2017 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 3,590 $ — $ — $ 3,590 U.S. government sponsored enterprise securities 4,985 — (2 ) 4,983 Corporate debt securities 1,184 — — 1,184 $ 9,759 $ — $ (2 ) $ 9,757 As of December 31, 2017, one |
Note 5 - Fair Value Measurement
Note 5 - Fair Value Measurement and Financial Instruments | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 5. Fair value measurement and financial instruments As of June 30, 2018, $18.0 three five one 1 2 2 third 3 The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands): June 3 0 , 2018 Level 1 Level 2 Level 3 Assets: Money market funds $ 471 $ 471 $ — $ — Commercial paper 15,029 — 15,029 — U.S. government sponsored enterprise securities 2,494 — 2,494 — Total assets $ 17,994 $ 471 $ 17,523 $ — Liabilities: Warrant liability $ 10,099 $ — $ — $ 10,099 Total liabilities $ 10,099 $ — $ — $ 10,099 December 31, 2017 Level 1 Level 2 Level 3 Assets: Money market funds $ 34 $ 34 $ — $ — Commercial paper 19,020 — 19,020 — U.S. government sponsored enterprise securities 4,983 — 4,983 — Corporate debt securities 1,184 — 1,184 — Total assets $ 25,221 $ 34 $ 25,187 $ — Liabilities: Warrant liability $ 10,089 $ — $ — $ 10,089 Total liabilities $ 10,089 $ — $ — $ 10,089 Warrant liability In connection with the offering completed on May 11, 2016, 1,785,714 may May 11, 2016, June 30, 2018, 10,000 May 11, 2016 June 30, 2018. June 3 0 , 2018 December 31, 2017 Stock price $ 2.81 $ 2.27 Exercise price $ 1.40 $ 1.40 Risk-free interest rate 2.60 % 2.01 % Volatility 117.59 % 143.57 % Dividend yield 0.00 % 0.00 % Expected life in years 2.86 3.36 Calculated fair value per warrant $ 2.22 $ 1.95 In connection with the offering completed on August 26, 2016, 5,606,250 may August 26, 2016, June 30, 2018, 5.6 June 3 0 , 2018 December 31, 2017 Stock price $ 2.81 $ 2.27 Exercise price $ 4.00 $ 4.00 Risk-free interest rate 2.62 % 2.04 % Volatility 112.83 % 145.36 % Dividend yield 0.00 % 0.00 % Expected life in years 3.16 3.65 Calculated fair value per warrant $ 1.80 $ 1.80 The following table presents a reconciliation of the warrant liability measured at fair value using unobservable inputs (Level 3 Warrant Liability Liabilities: Balance at January 1, 2018 $ 10,089 Change in the fair value of warrant liability 10 Balance at June 30, 2018 $ 10,099 The Company recognizes transfers into and out of levels within the fair value hierarchy at the end of the reporting period in which the actual event or change in circumstances that caused the transfer occurs. There were no |
Note 6 - Prepaid Expenses
Note 6 - Prepaid Expenses | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Prepaid Expenses and Other Assets [Text Block] | 6. Prepaid expenses Prepaid expenses as of June 30, 2018 December 31, 2017 June 30, 2018 December 31, 2017 Prepaid insurance $ 46 $ 233 Prepaid research and development expenses 907 709 Other prepaid expenses 102 70 Prepaid expenses and other current assets $ 1,055 $ 1,012 As of June 30, 2018 December 31, 2017, $0.9 $0.7 third |
Note 7 - Accrued Expenses
Note 7 - Accrued Expenses | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 7. Accrued expenses Accrued expenses as of June 30, 2018 December 31, 2017 June 30 , 2018 December 31, 2017 Accrued personnel related costs $ 376 $ 904 Accrued interest 39 41 Accrued research and development expenses 1,936 273 Accrued audit and tax services 247 246 Other accrued expenses 64 35 Accrued expenses $ 2,662 $ 1,499 |
Note 8 - Promissory Notes
Note 8 - Promissory Notes | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 8. Promissory notes On September 8, 2017, two first $7.0 second not $3.0 $20.0 December 31, 2018 2b December 31, 2018. The principal borrowed under the first $7.0 6.75% 1% 3% September 1, 2021, 5% $7.0 September 2018 36 Pursuant to the first 99,526 $2.11 seven $0.2 1.9%, 113.9%, 0% 7. $7.0 September 30, 2017, 3 $7.0 The third $0.1 In connection with the loan, the Company granted to Silicon Valley Bank a security interest in all of the Company’s personal property now owned or hereafter acquired, excluding intellectual property and certain other assets. The Company is not June 30, 2018, may As of June 30, 2018, 2018 $ 584 2019 2,333 2020 2,333 2021 2,100 Total $ 7,350 The following table shows actual interest expense, amortization of the debt discount and amortization of the issuance costs that was charged to interest expense (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Simple interest $ 119 $ — $ 237 $ — Accretion of debt discount 38 — 75 — Amortization of promissory note issuance costs 15 — 29 — Total $ 172 $ — $ 341 $ — The Company calculated the fair value of the secured promissory notes as $6.8 3 June 30, 2018. 6.75%, |
Note 9 - Revenue for License Ag
Note 9 - Revenue for License Agreement | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 9. Revenue for license agreement In April 2010, Pursuant to the agreement in 2010, $3.0 $72.0 $17.0 $5.0 $7.0 $5.0 $21.0 $7.0 $7.0 $7.0 $21.0 $7.0 $7.0 $7.0 $13.0 not $5.0 $8.0 may 20 29% Accounting for the Kissei Agreement prior to the Adoption of ASC Topic 606: The Company recognized the entire $3.0 2010. December 31, 2013, $5.0 No Accounting for the Kissei Agreement after the Adoption of Topic 606: Effective January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 The Company has reviewed its agreement with Kissei and determined that Kissei met the definition of a customer as defined in Topic 606. The Company determined that the license provided to Kissei represents a right to use functional intellectual property. This determination is based upon Kissei’s ability to use the license as soon as it was granted and that the Company has no not no no $3.0 2010. As outlined above the agreement also includes development and sales-based milestone payments and sales-based royalties. Upon the signing of the agreement, the development based milestone payments would have been considered variable consideration under Topic 606 third not no may no $5.0 December 31, 2013 606 no $5.0 2013. Topic 606 not no no Based on the above, the Company’s adoption of Topic 606 not no 606. |
Note 10 - Stock-based Compensat
Note 10 - Stock-based Compensation Plan | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 10. Stock-based compensation plan The Company’s Amended and Restated 2011 As of June 30, 2018, 71,000 The Company recognized stock-based compensation expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and development $ 47 $ 130 $ 105 $ 255 General and administrative 143 335 316 612 Total $ 190 $ 465 $ 421 $ 867 As of June 30, 2018 $0.6 eleven The following table summarizes stock option activity, including options issued to employees, directors and non-employees (in thousands, except per share): Options Weighted Average Outstanding at January 1, 2018 2,931 $ 3.10 Options granted 80 2.91 Options expired (71 ) 13.16 Outstanding at June 30, 2018 2,940 $ 2.85 The total amount of options expired for the six June 30, 2018 The fair values of options granted during the six June 30, 2018 2017 Six Months Ended June 30, 2018 2017 Expected life of the option term (years) 4.7 4.1 Risk-free interest rate 2.67 % 1.61 % Dividend rate 0 % 0 % Volatility 126.2 % 144.8 % |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 11. Commitments and contingencies Purchase commitments The Company is required to schedule certain manufacturing activities in advance. If the Company cancels any of these scheduled activities without proper notice the Company could be required to pay penalties of 50% 100% $1.7 June 30, 2018 All amounts recorded under these manufacturing contracts, including scheduled manufacturing activities and other activities, included as a component of research and development expense was $1.8 $0.1 three June 30, 2018 2017, $3.6 $0.1 six June 30, 2018 2017, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2018 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Basis of consolidation The condensed consolidated financial statements include the accounts of the Company, Sophiris Bio Corp. and Sophiris Bio Holding Corp. All intercompany balances and transactions have been eliminated for purposes of consolidation. |
Basis of Accounting, Policy [Policy Text Block] | Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, for the interim financial information and the rules and regulations of the Securities and Exchange Commission, or SEC, related to quarterly reports on Form 10 not 10 March 21, 2018. not not may During the six June 30, 2018, no 10 December 31, 2017, |
Revenue Recognition, Policy [Policy Text Block] | Revenue recognition Effective January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 606 The Company may may 606. The Company will then perform an analysis to determine the total transaction price that the Company expects to receive from satisfying the performance obligations in the agreement. To the extent that the agreement includes variable consideration, amounts which can vary depending on the occurrence or nonoccurrence of a future event, the amount included in the total transaction price may not not The calculated transaction price will then be allocated to the separate performance obligations based upon the relative standalone selling price of the performance obligations. If standalone selling price cannot be determined, a residual approach may For each performance obligation, the Company must determine the period over which the performance obligations will be satisfied, and revenue recognized. Revenue will be recognized over time if the Company satisfies the performance obligation over a period of time whereas revenue will be recognized at a point in time if the performance obligation is satisfied at a specific point in time. Revenue related to the transfer of an intellectual property license will be recognized either upon the transfer of the license or over a period of time depending upon whether or not not may |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent accounting pronouncements In February 2016, No. 2016 02, Leases (Topic 842 not December 15, 2018 In August 2016, 2016 15, "Statement of Cash Flows (Topic 230 eight first 2018, not In May 2017, No. 2017 09, "Compensation-Stock Compensation (Topic 718 2017 09. 718. first 2018, not |
Note 3 - Net Income (Loss) Pe18
Note 3 - Net Income (Loss) Per Common Share (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic net income (loss) per share Net income (loss) allocated to common stockholders $ (6,097 ) $ 610 $ (9,426 ) $ (2,010 ) Weighted average common shares outstanding-basic 30,111 30,111 30,111 30,111 Net income (loss) per share-basic $ (0.20 ) $ 0.02 $ (0.31 ) $ (0.07 ) Diluted net income (loss) per share Net income (loss) allocated to common stockholders-diluted $ (6,097 ) $ 603 $ (9,426 ) $ (2,010 ) Weighted average common shares outstanding-basic 30,111 30,111 30,111 30,111 Dilutive securities — 404 — — Weighted average common shares outstanding-dilutive 30,111 30,515 30,111 30,111 Net income (loss) per share-diluted $ (0.20 ) $ 0.02 $ (0.31 ) $ (0.07 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Options to purchase common shares 2,940 2,497 2,940 2,888 Common share purchase warrants 5,825 5,712 5,825 5,725 |
Note 4 - Securities Available19
Note 4 - Securities Available-for-sale (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Available-for-sale Securities [Table Text Block] | June 3 0 , 2018 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 2,093 $ — $ — $ 2,093 U.S. government sponsored enterprise securities 2,496 — (2 ) 2,494 $ 4,589 $ — $ (2 ) $ 4,587 December 31, 2017 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 3,590 $ — $ — $ 3,590 U.S. government sponsored enterprise securities 4,985 — (2 ) 4,983 Corporate debt securities 1,184 — — 1,184 $ 9,759 $ — $ (2 ) $ 9,757 |
Note 5 - Fair Value Measureme20
Note 5 - Fair Value Measurement and Financial Instruments (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | June 3 0 , 2018 Level 1 Level 2 Level 3 Assets: Money market funds $ 471 $ 471 $ — $ — Commercial paper 15,029 — 15,029 — U.S. government sponsored enterprise securities 2,494 — 2,494 — Total assets $ 17,994 $ 471 $ 17,523 $ — Liabilities: Warrant liability $ 10,099 $ — $ — $ 10,099 Total liabilities $ 10,099 $ — $ — $ 10,099 December 31, 2017 Level 1 Level 2 Level 3 Assets: Money market funds $ 34 $ 34 $ — $ — Commercial paper 19,020 — 19,020 — U.S. government sponsored enterprise securities 4,983 — 4,983 — Corporate debt securities 1,184 — 1,184 — Total assets $ 25,221 $ 34 $ 25,187 $ — Liabilities: Warrant liability $ 10,089 $ — $ — $ 10,089 Total liabilities $ 10,089 $ — $ — $ 10,089 |
Warrant Liability [Member] | |
Notes Tables | |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | June 3 0 , 2018 December 31, 2017 Stock price $ 2.81 $ 2.27 Exercise price $ 1.40 $ 1.40 Risk-free interest rate 2.60 % 2.01 % Volatility 117.59 % 143.57 % Dividend yield 0.00 % 0.00 % Expected life in years 2.86 3.36 Calculated fair value per warrant $ 2.22 $ 1.95 June 3 0 , 2018 December 31, 2017 Stock price $ 2.81 $ 2.27 Exercise price $ 4.00 $ 4.00 Risk-free interest rate 2.62 % 2.04 % Volatility 112.83 % 145.36 % Dividend yield 0.00 % 0.00 % Expected life in years 3.16 3.65 Calculated fair value per warrant $ 1.80 $ 1.80 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Warrant Liability Liabilities: Balance at January 1, 2018 $ 10,089 Change in the fair value of warrant liability 10 Balance at June 30, 2018 $ 10,099 |
Note 6 - Prepaid Expenses (Tabl
Note 6 - Prepaid Expenses (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Schedule of Prepaid Expense and Other Current Assets [Table Text Block] | June 30, 2018 December 31, 2017 Prepaid insurance $ 46 $ 233 Prepaid research and development expenses 907 709 Other prepaid expenses 102 70 Prepaid expenses and other current assets $ 1,055 $ 1,012 |
Note 7 - Accrued Expenses (Tabl
Note 7 - Accrued Expenses (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | June 30 , 2018 December 31, 2017 Accrued personnel related costs $ 376 $ 904 Accrued interest 39 41 Accrued research and development expenses 1,936 273 Accrued audit and tax services 247 246 Other accrued expenses 64 35 Accrued expenses $ 2,662 $ 1,499 |
Note 8 - Promissory Notes (Tabl
Note 8 - Promissory Notes (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Schedule of Maturities of Long-term Debt [Table Text Block] | 2018 $ 584 2019 2,333 2020 2,333 2021 2,100 Total $ 7,350 |
Contractual Interest Expense and Amortization of Debt Issuance Costs and Debt Discount [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Simple interest $ 119 $ — $ 237 $ — Accretion of debt discount 38 — 75 — Amortization of promissory note issuance costs 15 — 29 — Total $ 172 $ — $ 341 $ — |
Note 10 - Stock-based Compens24
Note 10 - Stock-based Compensation Plan (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Research and development $ 47 $ 130 $ 105 $ 255 General and administrative 143 335 316 612 Total $ 190 $ 465 $ 421 $ 867 |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Options Weighted Average Outstanding at January 1, 2018 2,931 $ 3.10 Options granted 80 2.91 Options expired (71 ) 13.16 Outstanding at June 30, 2018 2,940 $ 2.85 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Six Months Ended June 30, 2018 2017 Expected life of the option term (years) 4.7 4.1 Risk-free interest rate 2.67 % 1.61 % Dividend rate 0 % 0 % Volatility 126.2 % 144.8 % |
Note 1 - Nature of the Busine25
Note 1 - Nature of the Business (Details Textual) $ in Millions | Jun. 30, 2018USD ($) |
Cash, Cash Equivalents and Available-for-sale Securities | $ 18.5 |
Note 3 - Net Income (Loss) Pe26
Note 3 - Net Income (Loss) Per Common Share - Reconciliation of Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Basic net income (loss) per share | ||||
Net income (loss) allocated to common stockholders | $ (6,097) | $ 610 | $ (9,426) | $ (2,010) |
Weighted average common shares outstanding-basic (in shares) | 30,111 | 30,111 | 30,111 | 30,111 |
Net income (loss) per share-basic (in dollars per share) | $ (0.20) | $ 0.02 | $ (0.31) | $ (0.07) |
Diluted net income (loss) per share | ||||
Net income (loss) allocated to common stockholders-diluted | $ (6,097) | $ 603 | $ (9,426) | $ (2,010) |
Weighted average common shares outstanding-basic (in shares) | 30,111 | 30,111 | 30,111 | 30,111 |
Dilutive securities (in shares) | 404 | |||
Weighted average common shares outstanding-dilutive (in shares) | 30,111 | 30,515 | 30,111 | 30,111 |
Net income (loss) per share-diluted (in dollars per share) | $ (0.20) | $ 0.02 | $ (0.31) | $ (0.07) |
Note 3 - Net Income (Loss) Pe27
Note 3 - Net Income (Loss) Per Common Share - Potentially Dilutive Securities Excluded From Diluted Weighted-average Shares Outstanding (Details) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Employee Stock Option [Member] | ||||
Anti-dilutive securities excluded from computation of weighted-average shares outstanding (in shares) | 2,940 | 2,497 | 2,940 | 2,888 |
Warrant [Member] | ||||
Anti-dilutive securities excluded from computation of weighted-average shares outstanding (in shares) | 5,825 | 5,712 | 5,825 | 5,725 |
Note 4 - Securities Available28
Note 4 - Securities Available-for-sale - Securities Available-for-sale (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
Amortized Cost | $ 4,589 | $ 9,759 |
Unrealized Gain | ||
Unrealized Loss | (2) | (2) |
Estimated Fair Value | 4,587 | 9,757 |
Commercial Paper, Not Included with Cash and Cash Equivalents [Member] | ||
Amortized Cost | 2,093 | 3,590 |
Unrealized Gain | ||
Unrealized Loss | ||
Estimated Fair Value | 2,093 | 3,590 |
US Government-sponsored Enterprises Debt Securities [Member] | ||
Amortized Cost | 2,496 | 4,985 |
Unrealized Gain | ||
Unrealized Loss | (2) | (2) |
Estimated Fair Value | $ 2,494 | 4,983 |
Corporate Debt Securities [Member] | ||
Amortized Cost | 1,184 | |
Unrealized Gain | ||
Unrealized Loss | ||
Estimated Fair Value | $ 1,184 |
Note 5 - Fair Value Measureme29
Note 5 - Fair Value Measurement and Financial Instruments (Details Textual) - USD ($) $ in Thousands | Aug. 26, 2016 | May 11, 2016 | Jun. 30, 2018 | Dec. 31, 2017 |
Class of Warrant or Right, Issued During Period | 1,785,714 | |||
Warrants, Issued on May 11, 2016 [Member] | ||||
Class of Warrant or Right, Outstanding | 10,000 | |||
Warrants, Issued on August 26, 2016 [Member] | ||||
Class of Warrant or Right, Issued During Period | 5,606,250 | |||
Class of Warrant or Right, Outstanding | 5,600,000 | |||
Fair Value, Measurements, Recurring [Member] | ||||
Assets, Fair Value Disclosure | $ 17,994 | $ 25,221 |
Note 5 - Fair Value Measureme30
Note 5 - Fair Value Measurement and Financial Instruments - Assets and Liabilities Measured at Fair Value Measured on a Recurring Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
Debt securities available-for-sale | $ 4,587 | $ 9,757 |
US Government-sponsored Enterprises Debt Securities [Member] | ||
Debt securities available-for-sale | 2,494 | 4,983 |
Corporate Debt Securities [Member] | ||
Debt securities available-for-sale | 1,184 | |
Fair Value, Measurements, Recurring [Member] | ||
Commercial paper | 15,029 | 19,020 |
Total assets | 17,994 | 25,221 |
Total liabilities | 10,099 | 10,089 |
Fair Value, Measurements, Recurring [Member] | Warrant Liability [Member] | ||
Warrant liability | 10,099 | 10,089 |
Fair Value, Measurements, Recurring [Member] | US Government-sponsored Enterprises Debt Securities [Member] | ||
Debt securities available-for-sale | 2,494 | 4,983 |
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member] | ||
Debt securities available-for-sale | 1,184 | |
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Commercial paper | ||
Total assets | 471 | 34 |
Total liabilities | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Warrant Liability [Member] | ||
Warrant liability | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government-sponsored Enterprises Debt Securities [Member] | ||
Debt securities available-for-sale | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member] | ||
Debt securities available-for-sale | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Commercial paper | 15,029 | 19,020 |
Total assets | 17,523 | 25,187 |
Total liabilities | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Warrant Liability [Member] | ||
Warrant liability | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government-sponsored Enterprises Debt Securities [Member] | ||
Debt securities available-for-sale | 2,494 | 4,983 |
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member] | ||
Debt securities available-for-sale | 1,184 | |
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Commercial paper | ||
Total assets | ||
Total liabilities | 10,099 | 10,089 |
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] | ||
Warrant liability | 10,099 | 10,089 |
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government-sponsored Enterprises Debt Securities [Member] | ||
Debt securities available-for-sale | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member] | ||
Debt securities available-for-sale | ||
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | ||
Money market funds | 471 | 34 |
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Money market funds | 471 | 34 |
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Money market funds | ||
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Money market funds |
Note 5 - Fair Value Measureme31
Note 5 - Fair Value Measurement and Financial Instruments - Fair Value Assumptions, Warrant Liability (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018yr$ / shares | Dec. 31, 2017yr$ / shares | |
Warrants, Issued on May 11, 2016 [Member] | ||
Calculated fair value per warrant (in dollars per share) | $ / shares | $ 2.22 | $ 1.95 |
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Share Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 2.81 | 2.27 |
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Exercise Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 1.4 | 1.4 |
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.026 | 0.0201 |
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Price Volatility [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 1.1759 | 1.4357 |
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Expected Dividend Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 |
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Expected Term [Member] | ||
Warrants and Rights Outstanding, Measurement Input | yr | 2.86 | 3.36 |
Warrants, Issued on August 26, 2016 [Member] | ||
Calculated fair value per warrant (in dollars per share) | $ / shares | $ 1.80 | $ 1.80 |
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Share Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 2.81 | 2.27 |
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Exercise Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 4 | 4 |
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.0262 | 0.0204 |
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Price Volatility [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 1.1283 | 1.4536 |
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Expected Dividend Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 |
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Expected Term [Member] | ||
Warrants and Rights Outstanding, Measurement Input | yr | 3.16 | 3.65 |
Note 5 - Fair Value Measureme32
Note 5 - Fair Value Measurement and Financial Instruments - Fair Value Reconciliation of Warrant Liability (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Change in fair value warrant liability | $ 10 | $ (3,234) |
Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Balance | 10,089 | |
Change in fair value warrant liability | 10 | |
Balance | $ 10,099 |
Note 6 - Prepaid Expenses (Deta
Note 6 - Prepaid Expenses (Details Textual) - USD ($) $ in Millions | Jun. 30, 2018 | Dec. 31, 2017 |
Upfront Fees Included in Prepaid Researchs and Development Expenses | $ 0.9 | $ 0.7 |
Note 6 - Prepaid Expenses - Com
Note 6 - Prepaid Expenses - Components of Prepaid Expenses (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
Prepaid insurance | $ 46 | $ 233 |
Prepaid research and development expenses | 907 | 709 |
Other prepaid expenses | 102 | 70 |
Prepaid expenses and other current assets | $ 1,055 | $ 1,012 |
Note 7 - Accrued Expenses - Com
Note 7 - Accrued Expenses - Components of Accrued Expenses (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
Accrued personnel related costs | $ 376 | $ 904 |
Accrued interest | 39 | 41 |
Accrued research and development expenses | 1,936 | 273 |
Other accrued expenses | 64 | 35 |
Accrued expenses | 2,662 | 1,499 |
Accrued Audit and Tax Services [Member] | ||
Accrued audit and tax services | $ 247 | $ 246 |
Note 8 - Promissory Notes (Deta
Note 8 - Promissory Notes (Details Textual) - USD ($) | Sep. 08, 2017 | Jun. 30, 2018 | Sep. 30, 2017 |
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 99,526 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 2.11 | ||
Warrants Expiration Period | 7 years | ||
Warrants and Rights Outstanding | $ 200,000 | ||
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Warrants and Rights Outstanding, Measurement Input | 0.019 | ||
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Price Volatility [Member] | |||
Warrants and Rights Outstanding, Measurement Input | 1.139 | ||
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Expected Dividend Rate [Member] | |||
Warrants and Rights Outstanding, Measurement Input | 0 | ||
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Expected Term [Member] | |||
Warrants and Rights Outstanding, Measurement Input | 7 | ||
Silicon Valley Bank Loan [Member] | |||
Long-term Debt, Fair Value | $ 6,800,000 | $ 7,000,000 | |
Payments of Debt Issuance Costs | $ 100,000 | ||
Silicon Valley Bank Loan [Member] | Term Loan, First Tranche [Member] | |||
Debt Instrument, Face Amount | $ 7 | ||
Debt Instrument, Interest Rate, Stated Percentage | 6.75% | ||
Additional Fee Percentage | 5.00% | ||
Debt Instrument, Number of Monthly Payments | 36 | ||
Silicon Valley Bank Loan [Member] | Term Loan, First Tranche [Member] | Minimum [Member] | |||
Prepayment Fee Rate | 1.00% | ||
Silicon Valley Bank Loan [Member] | Term Loan, First Tranche [Member] | Maximum [Member] | |||
Prepayment Fee Rate | 3.00% | ||
Silicon Valley Bank Loan [Member] | Term Loan, Second Tranche [Member] | |||
Debt Instrument, Face Amount if Company Meets Requirements, Maximum | $ 3,000,000 | ||
Debt Instrument, Proceeds from Sale of Common Shares Required for Debt Issuance | $ 20,000,000 |
Note 8 - Promissory Notes - Fut
Note 8 - Promissory Notes - Future Contractual and Final Fee Payments (Details) $ in Thousands | Jun. 30, 2018USD ($) |
2,018 | $ 584 |
2,019 | 2,333 |
2,020 | 2,333 |
2,021 | 2,100 |
Total | $ 7,350 |
Note 8 - Promissory Notes - Act
Note 8 - Promissory Notes - Actual Interest Expense and Amortization of Debt Discount (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Simple interest | $ 119 | $ 237 | ||
Accretion of debt discount | 38 | 75 | ||
Amortization of promissory note issuance costs | 15 | 29 | ||
Total | $ 172 | $ 341 |
Note 9 - Revenue for License 39
Note 9 - Revenue for License Agreement (Details Textual) - Kissei Pharmaceuticals Co, Ltd. [Member] - USD ($) $ in Millions | 1 Months Ended | 6 Months Ended | 12 Months Ended | |
Apr. 30, 2010 | Jun. 30, 2018 | Dec. 31, 2013 | Dec. 31, 2010 | |
Upfront Payment Related to Licensing Agreement | $ 3 | |||
Non-refundable Milestone Payments Entitled to Receive | $ 72 | |||
Revenue Recognition, Milestone Method, Revenue Recognized | $ 5 | $ 3 | ||
Minimum [Member] | ||||
Percentage of Royalty Payable under Agreement | 20.00% | |||
Maximum [Member] | ||||
Percentage of Royalty Payable under Agreement | 29.00% | |||
Benign Prostate Hyperplasia [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | $ 17 | |||
Benign Prostate Hyperplasia [Member] | Development Activities [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 5 | |||
Benign Prostate Hyperplasia [Member] | Regulatory Approvals [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 7 | |||
Benign Prostate Hyperplasia [Member] | Gross Sale Targets [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 5 | |||
Prostate Cancer [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 21 | |||
Prostate Cancer [Member] | Development Activities [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 7 | |||
Prostate Cancer [Member] | Regulatory Approvals [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 7 | |||
Prostate Cancer [Member] | Gross Sale Targets [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 7 | |||
Prostatitis and Other Diseases of Prostate [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 21 | |||
Prostatitis and Other Diseases of Prostate [Member] | Development Activities [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 7 | |||
Prostatitis and Other Diseases of Prostate [Member] | Regulatory Approvals [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 7 | |||
Prostatitis and Other Diseases of Prostate [Member] | Gross Sale Targets [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 7 | |||
Milestones Not Associated with Indication [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 13 | |||
Milestones Not Associated with Indication [Member] | Regulatory Approvals [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | 5 | |||
Milestones Not Associated with Indication [Member] | Gross Sale Targets [Member] | ||||
Non-refundable Milestone Payments Entitled to Receive | $ 8 |
Note 10 - Stock-based Compens40
Note 10 - Stock-based Compensation Plan (Details Textual) $ in Millions | 6 Months Ended |
Jun. 30, 2018USD ($)shares | |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares | 71,000 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $ | $ 0.6 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 330 days |
Note 10 - Stock-based Compens41
Note 10 - Stock-based Compensation Plan - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Stock-based compensation expense | $ 190 | $ 465 | $ 421 | $ 867 |
Research and Development Expense [Member] | ||||
Stock-based compensation expense | 47 | 130 | 105 | 255 |
General and Administrative Expense [Member] | ||||
Stock-based compensation expense | $ 143 | $ 335 | $ 316 | $ 612 |
Note 10 - Stock-based Compens42
Note 10 - Stock-based Compensation Plan - Stock Option Activity (Details) shares in Thousands | 6 Months Ended |
Jun. 30, 2018$ / sharesshares | |
Options outstanding (in shares) | shares | 2,931 |
Weighted average exercise price - options outstanding (in dollars per share) | $ / shares | $ 3.10 |
Options granted (in shares) | shares | 80 |
Weighted average exercise price - options granted (in dollars per share) | $ / shares | $ 2.91 |
Options expired (in shares) | shares | (71) |
Weighted average exercise price - options expired (in dollars per share) | $ / shares | $ 13.16 |
Options outstanding (in shares) | shares | 2,940 |
Weighted average exercise price - options outstanding (in dollars per share) | $ / shares | $ 2.85 |
Note 10 - Stock-based Compens43
Note 10 - Stock-based Compensation Plan - Fair Value of Options Granted (Details) | 6 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Expected life of the option term (years) (Year) | 4 years 255 days | 4 years 36 days |
Risk-free interest rate | 2.67% | 1.61% |
Dividend rate | 0.00% | 0.00% |
Volatility | 126.20% | 144.80% |
Note 11 - Commitments and Con44
Note 11 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Purchase Commitment, Estimated Penalties | $ 1.7 | $ 1.7 | ||
Research and Development Expense [Member] | ||||
Purchase Commitment, Penalty Expense | $ 1.8 | $ 0.1 | $ 3.6 | $ 0.1 |
Minimum [Member] | ||||
Purchase Commitment, Percentage of Penalty to Pay, If Scheduled Activities Are Canceled Without Notice | 50.00% | 50.00% | ||
Maximum [Member] | ||||
Purchase Commitment, Percentage of Penalty to Pay, If Scheduled Activities Are Canceled Without Notice | 100.00% | 100.00% |